DART and laboratory monitoring of HIV treatment Reply

DART and laboratory monitoring of HIV treatment Reply

Bibliographic Details
Main Authors:	Walker, A, Mugyenyi, P, Munderi, P, Gibb, D, Gilks, C
Format:	Journal article
Published:	2010

Similar Items

Routine versus clinically driven laboratory monitoring of HIV antiretroviral therapy in Africa (DART): a randomised non-inferiority trial.
by: Mugyenyi, P, et al.
Published: (2010)

Prevalence, incidence and predictors of severe anaemia with zidovudine-containing regimens in African adults with HIV infection within the DART trial.
by: Ssali, F, et al.
Published: (2006)

Daily co-trimoxazole prophylaxis in severely immunosuppressed HIV-infected adults in Africa started on combination antiretroviral therapy: an observational analysis of the DART cohort.
by: Walker, A, et al.
Published: (2010)

Patterns of individual and population-level adherence to antiretroviral therapy and risk factors for poor adherence in the first year of the DART trial in Uganda and Zimbabwe.
by: Muyingo, S, et al.
Published: (2008)

Distribution of HLA-B alleles in a Ugandan HIV-infected adult population: NORA pharmacogenetic substudy of DART.
by: Munderi, P, et al.
Published: (2011)

Impact of second-line antiretroviral regimens on lipid profiles in an African setting: the DART trial sub-study.
by: Gomo, Z, et al.
Published: (2014)

High level of viral suppression and low switch rate to second-line antiretroviral therapy among HIV-infected adult patients followed over five years: retrospective analysis of the DART trial
by: Kityo, C, et al.
Published: (2014)

Pregnancy and infant outcomes among HIV-infected women taking long-term ART with and without tenofovir in the DART trial.
by: Gibb, D, et al.
Published: (2012)

A single CD4 test with 250 cells/mm3 threshold predicts viral suppression in HIV-infected adults failing first-line therapy by clinical criteria
by: Gilks, C, et al.
Published: (2013)

Severe renal dysfunction and risk factors associated with renal impairment in HIV-infected adults in Africa initiating antiretroviral therapy.
by: Reid, A, et al.
Published: (2008)

Nevirapine/zidovudine/lamivudine has superior immunological and virological responses not reflected in clinical outcomes in a 48-week randomized comparison with abacavir/zidovudine/lamivudine in HIV-infected Ugandan adults with low CD4 cell counts.
by: Munderi, P, et al.
Published: (2010)

Mortality in the year following antiretroviral therapy initiation in HIV-infected adults and children in Uganda and Zimbabwe.
by: Walker, A, et al.
Published: (2012)

Pregnancy and infant outcomes among HIV-infected women taking long-term ART with and without tenofovir in the DART trial.
by: Diana M Gibb, et al.
Published: (2012-01-01)

CD8 T-Cell Responses before and after Structured Treatment Interruption in Ugandan Adults Who Initiated ART with CD4 T Cells <200 Cell/μL: The DART Trial STI Substudy.
by: Serwanga, J, et al.
Published: (2011)

Opportunities for improving the efficiency of paediatric HIV treatment programmes.
by: Revill, P, et al.
Published: (2015)

Cost Effectiveness Analysis of Clinically Driven versus Routine Laboratory Monitoring of Antiretroviral Therapy in Uganda and Zimbabwe
by: Lara, A, et al.
Published: (2012)

High level of viral suppression and low switch rate to second-line antiretroviral therapy among HIV-infected adult patients followed over five years: retrospective analysis of the DART trial.
by: Cissy Kityo, et al.
Published: (2014-01-01)

The Impact of Different CD4 Cell-Count Monitoring and Switching Strategies on Mortality in HIV-Infected African Adults on Antiretroviral Therapy: An Application of Dynamic Marginal Structural Models.
by: Ford, D, et al.
Published: (2015)

Routine versus clinically driven laboratory monitoring and first-line antiretroviral therapy strategies in African children with HIV (ARROW): a 5-year open-label randomised factorial trial.
by: Kekitiinwa, A, et al.
Published: (2013)

The impact of different CD4 cell-count monitoring and switching strategies on mortality in HIV-infected African adults on antiretroviral therapy: an application of dynamic marginal structural models
by: Ford, D, et al.
Published: (2015)

CD8+ T-Cell Responses before and after Structured Treatment Interruption in Ugandan Adults Who Initiated ART with CD4+ T Cells <200 Cell/μL: The DART Trial STI Substudy
by: Jennifer Serwanga, et al.
Published: (2011-01-01)

Co-trimoxazole prophylaxis in African children with HIV-1 - Reply
by: Gibb, D, et al.
Published: (2005)

Estimating glomerular filtration rate in HIV-infected adults in Africa: comparison of Cockcroft-Gault and Modification of Diet in Renal Disease formulae.
by: Stöhr, W, et al.
Published: (2008)

Pharmacokinetics of lopinavir-ritonavir with and without nonnucleoside reverse transcriptase inhibitors in Ugandan HIV-infected adults.
by: Kityo, C, et al.
Published: (2010)

Clinical differences between younger and older adults with HIV/AIDS starting antiretroviral therapy in Uganda and Zimbabwe: a secondary analysis of the DART trial
by: Parikh, S, et al.
Published: (2013)

Cost effectiveness analysis of clinically driven versus routine laboratory monitoring of antiretroviral therapy in Uganda and Zimbabwe.
by: Antonieta Medina Lara, et al.
Published: (2012-01-01)

Monitoring of highly active antiretroviral therapy in HIV infection.
by: Walker, A, et al.
Published: (2011)

Nevirapine clearance from plasma in African adults stopping therapy: a pharmacokinetic substudy.
by: Kikaire, B, et al.
Published: (2007)

Sustainable and cost-effective monitoring of patients on ART
by: Diana M Gibb, et al.
Published: (2014-01-01)

Changes over time in creatinine clearance and comparison of emergent adverse events for HIV-positive adults receiving standard doses (300 mg/day) of lamivudine-containing antiretroviral therapy with baseline creatinine clearance of 30-49 vs ≥50 mL/min
by: Ross, LL, et al.
Published: (2019)

MONITORING LITHIUM TREATMENT - REPLY
by: Aronson, J, et al.
Published: (1993)

MONITORING THEOPHYLLINE TREATMENT - REPLY
by: Aronson, J, et al.
Published: (1993)

Glomerular dysfunction and associated risk factors over 4-5 years following antiretroviral therapy initiation in Africa.
by: Stöhr, W, et al.
Published: (2011)

Tuberculosis incidence is high in HIV-infected African children but is reduced by co-trimoxazole and time on antiretroviral therapy.
by: Crook, A, et al.
Published: (2016)

Clinical differences between younger and older adults with HIV/AIDS starting antiretroviral therapy in Uganda and Zimbabwe: a secondary analysis of the DART trial.
by: Sujal M Parikh, et al.
Published: (2013-01-01)

Objets d'art, oeuvres d'art
by: Muriel Verbeeck-Boutin
Published: (2008-10-01)

MONITORING TREATMENT WITH AMINOGLYCOSIDE ANTIBIOTICS - REPLY
by: Aronson, J, et al.
Published: (1993)

Reduced bacterial skin infections in HIV-infected African children randomized to long-term cotrimoxazole prophylaxis
by: Prendergast, A, et al.
Published: (2016)

Professor Raymond Dart
by: J. D. Verster
Published: (1961-06-01)

Progress and Challenges in Scaling Up Laboratory Monitoring of HIV Treatment.
by: Peter H Kilmarx, et al.
Published: (2016-08-01)